Anti-cardiolipin antibodies: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Anti-cardiolipin antibodies}} | |||
== | == Anti-cardiolipin antibodies == | ||
[[File:Antibody.svg|thumb|right|Diagram of an antibody structure]] | |||
Anti-cardiolipin antibodies are [[autoantibodies]] directed against [[cardiolipin]], a type of [[phospholipid]] found in the inner mitochondrial membrane. These antibodies are associated with several [[autoimmune diseases]], most notably the [[antiphospholipid syndrome]] (APS), which can lead to increased risk of [[thrombosis]] and [[pregnancy complications]]. | |||
== | == Structure and Function == | ||
Anti-cardiolipin antibodies | Anti-cardiolipin antibodies are typically of the [[IgG]], [[IgM]], or [[IgA]] isotypes. They are part of the body's [[immune response]] but mistakenly target the body's own tissues, leading to [[autoimmunity]]. The presence of these antibodies can disrupt normal [[coagulation]] processes, contributing to the formation of [[blood clots]]. | ||
== | == Clinical Significance == | ||
The | The detection of anti-cardiolipin antibodies is crucial in diagnosing [[antiphospholipid syndrome]], which is characterized by recurrent [[venous]] or [[arterial thrombosis]] and [[pregnancy morbidity]]. Patients with APS may experience [[deep vein thrombosis]], [[pulmonary embolism]], or [[stroke]]. In pregnant women, these antibodies can lead to [[recurrent miscarriage]], [[preeclampsia]], or [[intrauterine growth restriction]]. | ||
== | == Diagnosis == | ||
The presence of anti-cardiolipin antibodies is typically assessed using [[enzyme-linked immunosorbent assay]] (ELISA) tests. These tests measure the levels of antibodies in the blood and help in the diagnosis of APS and other related conditions. It is important to confirm the presence of these antibodies on two or more occasions, at least 12 weeks apart, to establish a diagnosis of APS. | |||
== | == Treatment == | ||
Management of patients with anti-cardiolipin antibodies involves reducing the risk of thrombosis. This may include the use of [[anticoagulants]] such as [[warfarin]] or [[heparin]], especially in patients with a history of thrombosis. In pregnant women, low-dose [[aspirin]] and [[heparin]] may be used to improve pregnancy outcomes. | |||
== Related pages == | |||
* [[Antiphospholipid syndrome]] | * [[Antiphospholipid syndrome]] | ||
* [[Autoimmune disease]] | * [[Autoimmune disease]] | ||
* [[ | * [[Thrombosis]] | ||
* [[ | * [[Pregnancy complications]] | ||
[[Category:Autoimmune diseases]] | [[Category:Autoimmune diseases]] | ||
[[Category: | [[Category:Antibodies]] | ||
Latest revision as of 11:12, 15 February 2025
Anti-cardiolipin antibodies[edit]
Anti-cardiolipin antibodies are autoantibodies directed against cardiolipin, a type of phospholipid found in the inner mitochondrial membrane. These antibodies are associated with several autoimmune diseases, most notably the antiphospholipid syndrome (APS), which can lead to increased risk of thrombosis and pregnancy complications.
Structure and Function[edit]
Anti-cardiolipin antibodies are typically of the IgG, IgM, or IgA isotypes. They are part of the body's immune response but mistakenly target the body's own tissues, leading to autoimmunity. The presence of these antibodies can disrupt normal coagulation processes, contributing to the formation of blood clots.
Clinical Significance[edit]
The detection of anti-cardiolipin antibodies is crucial in diagnosing antiphospholipid syndrome, which is characterized by recurrent venous or arterial thrombosis and pregnancy morbidity. Patients with APS may experience deep vein thrombosis, pulmonary embolism, or stroke. In pregnant women, these antibodies can lead to recurrent miscarriage, preeclampsia, or intrauterine growth restriction.
Diagnosis[edit]
The presence of anti-cardiolipin antibodies is typically assessed using enzyme-linked immunosorbent assay (ELISA) tests. These tests measure the levels of antibodies in the blood and help in the diagnosis of APS and other related conditions. It is important to confirm the presence of these antibodies on two or more occasions, at least 12 weeks apart, to establish a diagnosis of APS.
Treatment[edit]
Management of patients with anti-cardiolipin antibodies involves reducing the risk of thrombosis. This may include the use of anticoagulants such as warfarin or heparin, especially in patients with a history of thrombosis. In pregnant women, low-dose aspirin and heparin may be used to improve pregnancy outcomes.
